Skip to main content

Table 1 CSFV-specific neutralizing antibody titers in pigs immunized with BV-VSVG-ED-pFc-CMV-S/P-E2 at different days post-immunization

From: Surface displaying of swine IgG1 Fc enhances baculovirus-vectored vaccine efficacy by facilitating viral complement escape and mammalian cell transduction

Groups

Pig No.

Days post-immunization

0

7

14

21

28

NAbs

A

039

<1

<1

<1

<1

<1

 

075

<1

<1

<1

<1

<1

 

086

<1

<1

<1

<1

<1

 

116

<1

<1

<1

<1

<1

 

200

<1

<1

<1

<1

<1

 

\(\overline{X}\) ± S

<1

<1

<1

<1

<1

B

022

<1

6

16

64

128

 

046

<1

8

16

64

128

 

105

<1

6

16

64

128

 

142

<1

8

24

80

144

 

183

<1

8

16

64

108

 

\(\overline{X}\) ± S

<1

7.2 ± 1.1

17.6 ± 3.6

67.2 ± 7.2

131.5 ± 12.8

C

035

<1

6

8

16

44

 

056

<1

8

8

16

64

 

073

<1

6

8

32

64

 

117

<1

8

12

16

64

 

152

<1

4

8

16

64

 

\(\overline{X}\) ± S

<1

6.4 ± 1.7

8.8 ± 1.8

19.2 ± 7.2

60 ± 8.9

D

026

<1

6

12

48

84

 

084

<1

8

16

48

96

 

093

<1

6

12

64

96

 

128

<1

8

16

48

100

 

192

<1

4

16

64

88

 

\(\overline{X}\) ± S

<1

6.4 ± 1.7

14.4 ± 2.2

54.4 ± 8.8

95.2 ± 6.6

  1. Four groups (n = 5) of 4 week old pigs were immunized with BV-VSVG-ED-pFc-CMV-S/P-E2. Serum were collected at different time after the immunization, and subjected to detection of CSFV-specific neutralizing antibodies (NAbs) by serum-virus neutralization test (SNT). \(\overline{X}\) ± S: mean ± standard deviation. Group A-D indicate pigs immunized with PBS, CSFV commercial vaccine C-strain, BV-VSVG-ED-CMV-E2 and BV-VSVG-ED-pFc-CMV-S/P-E2, respectively.